Authors
Latest:
Forming Collaborations With the Physical Therapy Team in Cancer TreatmentPhysical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, DPT, PT.
Latest:
Fostering the Future of Psychosocial Care With World Psycho-Oncology DayIntegrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.
Latest:
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative TrialsThe June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.
Latest:
Maintenance Tucatinib Combo Yields PFS Extension in Advanced HER2+ Breast Cancer“HER2CLIMB-05 has demonstrated that the addition of tucatinib to HP represents an enhanced frontline maintenance therapy option for patients with HER2-positive metastatic breast cancer,” said Erika Hamilton, MD.
Latest:
Cellular Therapies Hold Promise in the Future of Melanoma Care“It’s a treatment for those patients who don’t have any other effective treatments available,” said Muhammad Umair Mushtaq, MD, on lifileucel in melanoma.
Latest:
Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 ScoreAbstract: Pancreatic neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms. They can be functioning tumors with secretion of a variety of peptide hormones, or nonfunctioning tumors with metastases to the liver at the time of diagnosis. Well-differentiated tumors tend to be slow-growing and characterized by low tumor mutational burden (TMB) and lower propensity to express PD-L1. Hypercalcemia due to malignancy can occur in about 20% to 30% of patients with cancer. The secretion of parathyroid hormone–related protein (PTH-rP) is among the causes of malignant hypercalcemia and has seldom been associated with hypercalcemia of NETs. Although the therapeutic landscape for neuroendocrine neoplasms has evolved substantially over the past decade, the role of immunotherapy has not yet been completely explored in this group of patients. We present a rare case of a metastatic pancreatic NET with high TMB, high PD-L1 tumor proportion score, and high PTH-rP–related hypercalcemia.
Latest:
HER2-Targeted Therapy in Upper GI CancerSam Klempner, MD, provides insight on HER2-targeted therapy for patients with upper GI cancer, and the Oncology Brothers recap the entire discussion.
Latest:
Clinical Pearls on Treating Patients with NRG1 FusionsTeresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, offer key takeaways and conclude their discussion by offering advice for clinicians treating patients with NRG1 fusion–positive malignancies.
Latest:
Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic ReviewDanazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Latest:
Breast Cancer Disparities May Fuel Guideline-Concordant Care ImprovementsMultidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Latest:
Detecting High-Risk Prostate Cancer Factors Can Inform Referral StrategiesAn expert from Dana-Farber Cancer Institute indicates that urologists should refer patients with prostate cancer who present with multiple high-risk factors at surgery to a radiation and medical oncologist.
Latest:
Incentivizing RCC Research Investment Across Lower-Income CountriesGiven resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Latest:
Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIsDr. Judd W. Moul, MD, and colleagues present the case of a man, aged 73 years, with a prostate-specific antigen level of 110 ng/mL after 4 negative prostate biopsies and 4 negative prostate MRIs.
